Treatment with coumarin to prevent or delay recurrence of malignant melanoma
- 1 January 1994
- journal article
- clinical trial
- Published by Springer Nature in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 120 (S1) , S32-S34
- https://doi.org/10.1007/bf01377122
Abstract
Both coumarin (1,2-benzopyrone) and warfarin (4-hydroxycoumarin) have been shown to prevent the recurrence of malignant melanoma. Their action is macrophage-dependent and the dosage is critical. In 1984 a multicentre, prospective, randomised, double-blind trial of coumarin, given as a daily 50-mg dose for 2 years after surgery in patients with high-risk melanoma, was started. The patients had lesions greater than 1.70 mm thick and TNM stage IB or stage II disease. To date there are 4 recurrences in the coumarin-treated group of 13 patients, and 10 recurrences in the placebo-treated group of 14 patients (P<0.01). There were no toxic effects.Keywords
This publication has 5 references indexed in Scilit:
- Synergistic effect of coumarin (1,2 benzopyrone) and endotoxin in the induction of human interleukin-1Clinical and Experimental Immunology, 1991
- The Rarity of Liver Toxicity in Patients Treated with Coumarin (1, 2-Benzopyrone)Human Toxicology, 1989
- Prevention of early recurrence of high risk malignant melanoma by coumarin. Irish Melanoma Group.1989
- The Natural Break Points for Primary-Tumor Thickness in Clinical Stage I MelanomaNew England Journal of Medicine, 1981
- INEFFECTIVENESS OF COUMARIN TREATMENT ON THERMAL EDEMA OF MACROPHAGE-FREE RATS1976